Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Daniel J Miller

Soumya P Sahoo

Hiroo Koyama

Sander G Mills

Malcolm MacCoss

Paul E Finke

Ranjit C Desai

Julia K Boueres

Shrenik K Shah

Yuan-Ching P Chiang

Laura C Meurer

Albert J Robichaud

Ginger Xu-Qiang Yang

Dennis J Underwood

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: Formula (I); are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. 

P38 kinase inhibiting agents

A class of N-cyclohexylaminocarbonyl benzenesulfonamide derivatives are agonists or partial agonists or antagonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

N-cyclohexylaminocarbonyl benzensulfonmide derivatives

A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders

Disclosed are substituted aryl piperazines of Formula I ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis. In particular compounds of Formula I are shown to be neurokinin antagonists.

Substituted aryl piperazines as neurokinin antagonists

Substituted alicyclic compounds of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma.

Alicyclic compounds as tachykinin receptor antagonists

Growing community of inventors

Edison, NJ, United States of America

Daniel J Miller